Atara Biotherapeutics Q4 2023 Earnings Report

Atara Biotherapeutics EPS Results

• Actual EPS: -$14.00
• Consensus EPS: -$15.25
• Beat/Miss: Beat by +$1.25
• One Year Ago EPS: N/A

Atara Biotherapeutics Revenue Results

• Actual Revenue: $4.25 million
• Expected Revenue: $2.45 million
• Beat/Miss: Beat by +$1.80 million
• YoY Revenue Growth: N/A

Atara Biotherapeutics Announcement Details

• Quarter: Q4 2023
• Date: 3/28/2024
• Time: N/A
• Conference Call Date: Thursday, March 28, 2024
• Conference Call Time: 7:00AM ET

Atara Biotherapeutics (NASDAQ:ATRA) engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.